PARP1 and brain cancer: However, PARP inhibitors have recently been investigated for their ability to sensitize brain cancer cells to chemotherapy and radiotherapy (Van Vuurden et al., 2011; Chornenkyy et al., 2015; Jue et al., 2017) and it is this approach that we sought to test in medulloblastoma.